Integra (IART) Up 2.3% Since Last Earnings Report: Can It Continue?

Core Viewpoint - Integra LifeSciences has seen a 2.3% increase in shares over the past month, underperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Estimates Movement - Fresh estimates for Integra have trended downward, with the consensus estimate shifting by -25.03% over the past month [2] VGM Scores - Integra has a subpar Growth Score of D and a Momentum Score of F, but it received an A for Value, placing it in the top quintile for this investment strategy. The overall aggregate VGM Score is C [3] Outlook - The downward trend in estimates indicates a negative outlook for Integra, reflected in its Zacks Rank of 4 (Sell), suggesting below-average returns in the coming months [4] Industry Performance - Integra is part of the Zacks Medical - Instruments industry. Teleflex, another player in the same industry, has gained 0.7% over the past month, reporting revenues of $700.67 million for the last quarter, which is a -5% year-over-year change [5] - Teleflex's expected earnings for the current quarter are $3.36 per share, indicating a -1.8% change from the previous year, and it also holds a Zacks Rank of 4 (Sell) [6]